Search

Your search keyword '"Alzheimer’s Disease Neuroimaging Initiative"' showing total 90 results
Start Over Author "Alzheimer’s Disease Neuroimaging Initiative" Journal alzheimer's & dementia
90 results on '"Alzheimer’s Disease Neuroimaging Initiative"'

1. Gene‐ and age‐informed screening for preclinical Alzheimer's disease trials

Author

Spencer, Barbara E, Digma, Leonardino A, Jennings, Robin G, Brewer, James B, and Team, for the Alzheimer's Disease Neuroimaging Initiative and the A4 Study

Subjects
Biomedical and Clinical Sciences, Biological Psychology, Clinical Sciences, Neurosciences, Psychology, Clinical Trials and Supportive Activities, Clinical Research, Alzheimer's Disease, Acquired Cognitive Impairment, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Brain Disorders, Neurodegenerative, Prevention, Dementia, Aging, Neurological, Aged, Alzheimer Disease, Amyloid beta-Peptides, Brain, Clinical Trials as Topic, Cohort Studies, Female, Humans, Male, Mass Screening, Positron-Emission Tomography, Prodromal Symptoms, Alzheimer&apos, s disease, biomarkers, clinical trial design, genetics, neuroimaging, PET, predictive markers, Alzheimer's Disease Neuroimaging Initiative and the A4 Study Team, Alzheimer's disease, Geriatrics, Clinical sciences, Biological psychology
Abstract

IntroductionElevated β-amyloid is used to enroll individuals into preclinical Alzheimer's disease trials, but the screening process is inefficient and expensive. Novel enrichment methods are needed to improve efficiency of enrollment.MethodsAlzheimer's disease incidence rates and a polygenic hazard score were used to create a gene- and age-defined ADAge. An ADAge cutpoint was chosen to optimally predict β-amyloid positivity among clinically normal Alzheimer's Disease Neuroimaging Initiative participants and applied to an independent Alzheimer's Disease Research Center validation cohort. The impact of ADAge enrichment on screening costs was evaluated in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease trial data.ResultsIn the validation cohort, the ADAge-enriched sample had a higher proportion of individuals with elevated β-amyloid (difference [95% CI] 0.19[0.07 to 0.33]) than the unenriched sample. ADAge enrichment lowered screening costs by $4.41 million (31.00%) in the real-world clinical trial scenario.DiscussionADAge enrichment provides for a more efficient and cost-effective means to enroll clinically normal individuals with elevated β-amyloid in clinical trials.

Published
2021

2. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers

Author

Nho, Kwangsik, Kueider‐Paisley, Alexandra, MahmoudianDehkordi, Siamak, Arnold, Matthias, Risacher, Shannon L, Louie, Gregory, Blach, Colette, Baillie, Rebecca, Han, Xianlin, Kastenmüller, Gabi, Jia, Wei, Xie, Guoxiang, Ahmad, Shahzad, Hankemeier, Thomas, van Duijn, Cornelia M, Trojanowski, John Q, Shaw, Leslie M, Weiner, Michael W, Doraiswamy, P Murali, Saykin, Andrew J, Kaddurah‐Daouk, Rima, and Consortium, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics

Subjects
Medical Biochemistry and Metabolomics, Biomedical and Clinical Sciences, Digestive Diseases, Aging, Neurosciences, Neurodegenerative, Alzheimer's Disease, Dementia, Brain Disorders, Acquired Cognitive Impairment, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Biomedical Imaging, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Aetiology, 2.1 Biological and endogenous factors, Neurological, Aged, Alzheimer Disease, Amyloid beta-Peptides, Bile Acids and Salts, Biomarkers, Cognitive Dysfunction, Female, Fluorodeoxyglucose F18, Humans, Magnetic Resonance Imaging, Male, Neuroimaging, Positron-Emission Tomography, Prospective Studies, tau Proteins, Metabolomics, Bile acid, Alzheimer's disease, Amyloid-beta, CSF biomarkers, Brain glucose metabolism, PET, MRI, Gut-liver-brain axis, Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium, Amyloid-β, Clinical Sciences, Geriatrics, Clinical sciences, Biological psychology
Abstract

IntroductionBile acids (BAs) are the end products of cholesterol metabolism produced by human and gut microbiome co-metabolism. Recent evidence suggests gut microbiota influence pathological features of Alzheimer's disease (AD) including neuroinflammation and amyloid-β deposition.MethodSerum levels of 20 primary and secondary BA metabolites from the AD Neuroimaging Initiative (n = 1562) were measured using targeted metabolomic profiling. We assessed the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF) biomarkers, atrophy (magnetic resonance imaging), and brain glucose metabolism ([18F]FDG PET).ResultsOf 23 BAs and relevant calculated ratios after quality control procedures, three BA signatures were associated with CSF Aβ1-42 ("A") and three with CSF p-tau181 ("T") (corrected P

Published
2019

3. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome

Author

MahmoudianDehkordi, Siamak, Arnold, Matthias, Nho, Kwangsik, Ahmad, Shahzad, Jia, Wei, Xie, Guoxiang, Louie, Gregory, Kueider‐Paisley, Alexandra, Moseley, M Arthur, Thompson, J Will, St John Williams, Lisa, Tenenbaum, Jessica D, Blach, Colette, Baillie, Rebecca, Han, Xianlin, Bhattacharyya, Sudeepa, Toledo, Jon B, Schafferer, Simon, Klein, Sebastian, Koal, Therese, Risacher, Shannon L, Kling, Mitchel Allan, Motsinger‐Reif, Alison, Rotroff, Daniel M, Jack, John, Hankemeier, Thomas, Bennett, David A, De Jager, Philip L, Trojanowski, John Q, Shaw, Leslie M, Weiner, Michael W, Doraiswamy, P Murali, van Duijn, Cornelia M, Saykin, Andrew J, Kastenmüller, Gabi, Kaddurah‐Daouk, Rima, and Consortium, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics

Subjects
Biological Psychology, Psychology, Digestive Diseases, Aging, Neurosciences, Neurodegenerative, Alzheimer's Disease, Dementia, Brain Disorders, Acquired Cognitive Impairment, Genetics, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Behavioral and Social Science, Aetiology, 2.1 Biological and endogenous factors, Neurological, Aged, Alzheimer Disease, Bile Acids and Salts, Cognitive Dysfunction, Dysbiosis, Female, Gastrointestinal Microbiome, Humans, Liver, Male, Metabolome, Metabolomics, Lipidomics, Alzheimer's disease, Gut microbiome, Gut-liver-brain axis, Atlas for Alzheimer, Genetic variants, Immunity, Inflammation, Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium, Clinical Sciences, Geriatrics, Clinical sciences, Biological psychology
Abstract

IntroductionIncreasing evidence suggests a role for the gut microbiome in central nervous system disorders and a specific role for the gut-brain axis in neurodegeneration. Bile acids (BAs), products of cholesterol metabolism and clearance, are produced in the liver and are further metabolized by gut bacteria. They have major regulatory and signaling functions and seem dysregulated in Alzheimer's disease (AD).MethodsSerum levels of 15 primary and secondary BAs and their conjugated forms were measured in 1464 subjects including 370 cognitively normal older adults, 284 with early mild cognitive impairment, 505 with late mild cognitive impairment, and 305 AD cases enrolled in the AD Neuroimaging Initiative. We assessed associations of BA profiles including selected ratios with diagnosis, cognition, and AD-related genetic variants, adjusting for confounders and multiple testing.ResultsIn AD compared to cognitively normal older adults, we observed significantly lower serum concentrations of a primary BA (cholic acid [CA]) and increased levels of the bacterially produced, secondary BA, deoxycholic acid, and its glycine and taurine conjugated forms. An increased ratio of deoxycholic acid:CA, which reflects 7α-dehydroxylation of CA by gut bacteria, strongly associated with cognitive decline, a finding replicated in serum and brain samples in the Rush Religious Orders and Memory and Aging Project. Several genetic variants in immune response-related genes implicated in AD showed associations with BA profiles.DiscussionWe report for the first time an association between altered BA profile, genetic variants implicated in AD, and cognitive changes in disease using a large multicenter study. These findings warrant further investigation of gut dysbiosis and possible role of gut-liver-brain axis in the pathogenesis of AD.

Published
2019

4. Whole‐exome rare‐variant analysis of Alzheimer's disease and related biomarker traits

Author

Alzheimer's Disease Neuroimaging Initiative (ADNI), Küçükali, Fahri, Neumann, Alexander, Van Dongen, Jasper, De Pooter, Tim, Joris, Geert, De Rijk, Peter, Ohlei, Olena, Dobricic, Valerija, Bos, Isabelle, Vos, Stephanie J B, Engelborghs, Sebastiaan, De Roeck, Ellen, Vandenberghe, Rik, Gabel, Silvy, Meersmans, Karen, Tsolaki, Magda, Verhey, Frans, Martinez-Lage, Pablo, Tainta, Mikel, Frisoni, Giovanni, Blin, Oliver, Richardson, Jill C, Bordet, Régis, Scheltens, Philip, Popp, Julius, Peyratout, Gwendoline, Johannsen, Peter, Frölich, Lutz, Freund-Levi, Yvonne, Streffer, Johannes, Lovestone, Simon, Legido-Quigley, Cristina, Kate, Mara Ten, Barkhof, Frederik, Zetterberg, Henrik, Bertram, Lars, Strazisar, Mojca, Visser, Pieter Jelle, Van Broeckhoven, Christine, Sleegers, Kristel, Alzheimer’s Disease Neuroimaging Initiative (ADNI), EMIF-ADStudyGroup, Epidemiology, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Amsterdam Neuroscience - Neurodegeneration, Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, and Amsterdam Neuroscience - Neuroinfection & -inflammation

Subjects
D-RIBOSE, Epidemiology, Endophenotypes, Neuroscience(all), Clinical Neurology, ABCA7, Cellular and Molecular Neuroscience, Developmental Neuroscience, SDG 3 - Good Health and Well-being, GWAS, whole-exome sequencing, GENOME-WIDE ASSOCIATION, METAANALYSIS, Science & Technology, ENDOPHENOTYPES, MUTATIONS, Health Policy, neurology, biomarkers, rare coding variants, Alzheimer's disease, FRAMEWORK, Psychiatry and Mental health, Whole-exome sequencing, COGNITIVE DECLINE, Neurology (clinical), Neurosciences & Neurology, Human medicine, Geriatrics and Gerontology, Life Sciences & Biomedicine
Abstract

INTRODUCTION: Despite increasing evidence of a role of rare genetic variation in the risk of Alzheimer's disease (AD), limited attention has been paid to its contribution to AD-related biomarker traits indicative of AD-relevant pathophysiological processes. METHODS: We performed whole-exome gene-based rare-variant association studies (RVASs) of 17 AD-related traits on whole-exome sequencing (WES) data generated in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study (n = 450) and whole-genome sequencing (WGS) data from ADNI (n = 808). RESULTS: Mutation screening revealed a novel probably pathogenic mutation (PSEN1 p.Leu232Phe). Gene-based RVAS revealed the exome-wide significant contribution of rare coding variation in RBKS and OR7A10 to cognitive performance and protection against left hippocampal atrophy, respectively. DISCUSSION: The identification of these novel gene-trait associations offers new perspectives into the role of rare coding variation in the distinct pathophysiological processes culminating in AD, which may lead to identification of novel therapeutic and diagnostic targets. ispartof: ALZHEIMERS & DEMENTIA vol:19 issue:6 ispartof: location:United States status: Published online

Published
2023

5. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum

Author

William J. Jagust, Leslie M. Shaw, Andrew J. Saykin, John Q. Trojanowski, Alzheimer’s Disease Neuroimaging Initiative, Ronald C. Petersen, Dallas P. Veitch, Daniel Weintraub, Clifford R. Jack, Michael W. Weiner, Paul S. Aisen, Zeynep Demir, and Duygu Tosun

Subjects
Oncology, Apolipoprotein E, medicine.medical_specialty, Epidemiology, Amyloid beta, tau Proteins, Cellular and Molecular Neuroscience, Atrophy, Developmental Neuroscience, Alzheimer Disease, Risk Factors, Internal medicine, medicine, Humans, Dementia, Cognitive Dysfunction, Cognitive decline, Aged, Amyloid beta-Peptides, biology, business.industry, Health Policy, Neurodegeneration, Brain, Cognition, medicine.disease, Hyperintensity, Psychiatry and Mental health, Cross-Sectional Studies, Positron-Emission Tomography, biology.protein, Neurology (clinical), Geriatrics and Gerontology, business, Biomarkers
Abstract

Introduction Amyloid beta (Aβ), tau, and neurodegeneration jointly with the Alzheimer's disease (AD) risk factors affect the severity of clinical symptoms and disease progression. Methods Within 248 Aβ-positive elderly with and without cognitive impairment and dementia, partial least squares structural equation pathway modeling was used to assess the direct and indirect effects of imaging biomarkers (global Aβ-positron emission tomography [PET] uptake, regional tau-PET uptake, and regional magnetic resonance imaging-based atrophy) and risk-factors (age, sex, education, apolipoprotein E [APOE], and white-matter lesions) on cross-sectional cognitive impairment and longitudinal cognitive decline. Results Sixteen percent of variance in cross-sectional cognitive impairment was accounted for by Aβ, 46% to 47% by tau, and 25% to 29% by atrophy, although 53% to 58% of total variance in cognitive impairment was explained by incorporating mediated and direct effects of AD risk factors. The Aβ-tau-atrophy pathway accounted for 50% to 56% of variance in longitudinal cognitive decline while Aβ, tau, and atrophy independently explained 16%, 46% to 47%, and 25% to 29% of the variance, respectively. Discussion These findings emphasize that treatments that remove Aβ and completely stop downstream effects on tau and neurodegeneration would only be partially effective in slowing of cognitive decline or reversing cognitive impairment.

Published
2021

6. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

Author

Paul S. Aisen, Michael W. Weiner, Danielle J Harvey, William J. Jagust, John Q. Trojanowski, Robert C. Green, Alzheimer’s Disease Neuroimaging Initiative, Susan M. Landau, Arthur W. Toga, Leslie M. Shaw, Ronald C. Petersen, Monica Rivera-Mindt, Duygu Tosun, Richard J. Perrin, John C. Morris, Laurel A. Beckett, Andrew J. Saykin, Clifford R. Jack, Ozioma C. Okonkwo, Dallas P. Veitch, and Charles DeCarli

Subjects
Oncology, Aging, Epidemiology, Disease, Neurodegenerative, Alzheimer's Disease, tau, screening and diagnosis, biology, Health Policy, AV1541 tau positron emission tomography, amyloid, plasma biomarker, Detection, Psychiatry and Mental health, Neurological, Cohort, Disease Progression, Biomedical Imaging, Alzheimer's Disease Neuroimaging Initiative, medicine.medical_specialty, Amyloid beta, Clinical Sciences, Neuroimaging, tau Proteins, Cellular and Molecular Neuroscience, disease progression, mild cognitive impairment, Developmental Neuroscience, Alzheimer Disease, Internal medicine, mental disorders, Acquired Cognitive Impairment, medicine, Humans, Cognitive Dysfunction, Amyloid beta-Peptides, Vascular disease, business.industry, Prevention, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), medicine.disease, Brain Disorders, 4.1 Discovery and preclinical testing of markers and technologies, Biomarker (cell), Clinical trial, Geriatrics, biology.protein, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Biomarkers
Abstract

INTRODUCTION The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. METHODS We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. RESULTS Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. DISCUSSION ADNI has had a profound impact in improving clinical trials for AD.

Published
2021

7. Effect of periodontal treatment on preclinical Alzheimer's disease—Results of a trial emulation approach

Author

Alzheimer’s Disease Neuroimaging Initiative, Hans J. Grabe, Robin Bülow, Birte Holtfreter, Reiner Biffar, Nele Friedrich, Sandra Van der Auwera, Thomas Kocher, Christian Schwahn, Christiane Pink, Stefan Frenzel, and Henry Völzke

Subjects
Male, Aging, Epidemiology, epidemiology [Periodontal Diseases], Cohort Studies, pathology [Alzheimer Disease], pathology [Aging], 0302 clinical medicine, pathology [Brain], Risk Factors, Germany, Longitudinal Studies, pathology [Atrophy], education.field_of_study, medicine.diagnostic_test, Health Policy, Brain, Middle Aged, Alzheimer's disease, Magnetic Resonance Imaging, Psychiatry and Mental health, Study of Health in Pomerania, Cohort, Female, epidemiology, periodontal diseases, Adult, medicine.medical_specialty, Population, epidemiology [Germany], Prodromal Symptoms, 03 medical and health sciences, Cellular and Molecular Neuroscience, Atrophy, Developmental Neuroscience, Alzheimer Disease, Internal medicine, medicine, Humans, ddc:610, education, Periodontal Diseases, Periodontitis, business.industry, aging, Magnetic resonance imaging, 030206 dentistry, medicine.disease, Confidence interval, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery
Abstract

Introduction We investigated the relationship between periodontal treatment and pre-clinical Alzheimer's disease (AD). Methods In this quasi-experimental design, 177 periodontally treated patients from the "Greifswald Approach to Individualized Medicine" cohort, which used the same protocols as the population-based Study of Health in Pomerania TREND (SHIP-TREND), and 409 untreated subjects from SHIP-TREND were analyzed. Subjects were younger than 60 years at the magnetic resonance imaging examination, with a median observation period of 7.3 years. Imaging markers for brain atrophy in late-onset AD and brain aging were used as the outcomes. Results Robust to sensitivity analyses, periodontal treatment had a favorable effect on AD-related brain atrophy (-0.41; 95% confidence interval: -0.70 to -0.12; P = .0051), which corresponds to a shift from the 50th to the 37th percentile of the outcome distribution. For brain aging, the treatment effect was uncertain. Conclusion Periodontitis is related to pre-clinical AD in our population.

Published
2021

8. Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts

Author

Judy Pa, Xinkun Wang, Prabhakar Chalise, Russell H. Swerdlow, Elias K. Michaelis, Jill K. Morris, Dongwei Hui, Jonathan D. Mahnken, Palash Sharma, Shea J. Andrews, Jeffrey M. Burns, Mary L. Michaelis, Heather M. Wilkins, and Alzheimer’s Disease Neuroimaging Initiative

Subjects
Male, 0301 basic medicine, Apolipoprotein E, Mitochondrial DNA, Epidemiology, Biology, DNA, Mitochondrial, Article, Haplogroup, Cohort Studies, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Developmental Neuroscience, Alzheimer Disease, Humans, Genetic Predisposition to Disease, Longitudinal Studies, Aged, Genetics, Health Policy, Odds ratio, Exploratory analysis, Middle Aged, Psychiatry and Mental health, 030104 developmental biology, Haplotypes, Female, Neurology (clinical), Geriatrics and Gerontology, 030217 neurology & neurosurgery, Human mitochondrial DNA haplogroup
Abstract

Introduction Inherited mitochondrial DNA (mtDNA) variants may influence Alzheimer's disease (AD) risk. Methods We sequenced mtDNA from 146 AD and 265 cognitively normal (CN) subjects from the University of Kansas AD Center (KUADC) and assigned haplogroups. We further considered 244 AD and 242 CN AD Neuroimaging Initiative (ADNI) subjects with equivalent data. Results Without applying multiple comparisons corrections, KUADC haplogroup J AD and CN frequencies were 16.4% versus 7.6% (P = .007), and haplogroup K AD and CN frequencies were 4.8% versus 10.2% (P = .063). ADNI haplogroup J AD and CN frequencies were 10.7% versus 7.0% (P = .20), and haplogroup K frequencies were 4.9% versus 8.7% (P = .11). For the combined 390 AD and 507 CN cases haplogroup J frequencies were 12.8% versus 7.3% (P = .006), odds ratio (OR) = 1.87, and haplogroup K frequencies were 4.9% versus 9.5% (P = .010), OR = 0.49. Associations remained significant after adjusting for apolipoprotein E, age, and sex. Conclusion This exploratory analysis suggests inherited mtDNA variants influence AD risk.

Published
2020

9. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach

Author

Fabian Model, Michael C. Donohue, Nicola Volye, Alzheimer’s Disease Neuroimaging Initiative, Michael S. Rafii, Paul S. Aisen, Paul Delmar, and Hong Liu-Seifert

Subjects
Male, medicine.medical_specialty, Randomization, Epidemiology, Neuroimaging, Disease, Article, 03 medical and health sciences, Cellular and Molecular Neuroscience, Cognition, 0302 clinical medicine, Developmental Neuroscience, Alzheimer Disease, Experimental therapy, Humans, Medicine, Cognitive Dysfunction, Prospective Studies, 030212 general & internal medicine, Intensive care medicine, Cognitive impairment, Aged, Clinical Trials as Topic, business.industry, Health Policy, Clinical trial, Psychiatry and Mental health, Disease Progression, Female, Observational study, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery
Abstract

In clinical trials in populations with mild cognitive impairment, it is common for participants to initiate concurrent symptomatic medications for Alzheimer's disease after randomization to the experimental therapy. One strategy for addressing this occurrence is to exclude any observations that occur after the concurrent medication is initiated. The rationale for this approach is that these observations might reflect a symptomatic benefit of the concurrent medication that would adversely bias efficacy estimates for an effective experimental therapy. We interrogate the assumptions underlying such an approach by estimating the effect of newly prescribed concurrent medications in an observational study, the Alzheimer's Disease Neuroimaging Initiative.

Published
2020

10. Higher TREM2 levels and microglia activation associated with slower rates of amyloid PET increase in humans and a transgenic mouse model of beta‐amyloid

Author

Matthias Brendel, Christian Sacher, Christian Haass, Mark Suarez‐Calvet, Tanja Blume, Gloria Biechele, Nicolai Franzmeier, Alzheimer’s Disease Neuroimaging Initiative, and Michael Ewers

Subjects
Genetically modified mouse, Tau pathology, Amyloid, Microglia, Epidemiology, TREM2, business.industry, Health Policy, Amyloid pet, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.anatomical_structure, Developmental Neuroscience, medicine, Cancer research, Neurology (clinical), Geriatrics and Gerontology, Beta (finance), business
Published
2020

11. Doing more with less: Women’s higher brain metabolic rate compensates for early Alzheimer’s pathological changes

Author

Sarah Reddy, Anat Biegon, Pauline M. Maki, Alzheimer’s Disease Neuroimaging Initiative, Mark W. Bondi, and Erin E. Sundermann

Subjects
Gerontology, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Metabolic rate, Medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, Resilience (network), business, Pathological
Published
2020

12. Accumulating and heterogeneous network‐knockout profiles in amnestic mild cognitive impairment and Alzheimer’s disease dementia

Author

Alzheimer’s Disease Neuroimaging Initiative, Misic Bratislav, Donald T. Stuss, Sean M. Nestor, Mario Masellis, Simon J. Graham, Sandra E. Black, Joel Ramirez, and Nicolaas Paul L.G. Verhoeff

Subjects
Epidemiology, business.industry, Health Policy, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, Cognitive impairment, business, Neuroscience, Heterogeneous network
Published
2020

13. Pathological correlates of impaired self‐awareness of memory function in dementia

Author

Patrizia Vannini, Cristina Lois, Bernard Hanseeuw, Alzheimer’s Disease Neuroimaging Initiative, Madeline Kuppe, and Geoffroy Gagliardi

Subjects
Epidemiology, business.industry, Health Policy, media_common.quotation_subject, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Self-awareness, Medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Function (engineering), Pathological, Clinical psychology, media_common
Published
2020

14. Modeling patient‐specific tau spreading patterns in Alzheimer’s disease: Towards precision medicine

Author

Lukas Frontzkowski, Michael Ewers, Julia Neitzel, Rik Ossenkoppele, Olof Strandberg, Alzheimer’s Disease Neuroimaging Initiative, BioFINDER, Anna Rubinski, Nicolai Franzmeier, Ruben Smith, and Oskar Hansson

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Person centered, Disease, Patient specific, Precision medicine, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Physical medicine and rehabilitation, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2020

15. Variability in tau‐atrophy relationships reveals underlying phenotypes in individuals on the Alzheimer’s disease continuum

Author

Paul A. Yushkevich, Robin de Flores, Sandhitsu R. Das, Long Xie, Brad C. Dickerson, David A. Wolk, Alzheimer’s Disease Neuroimaging Initiative, David J. Irwin, Ilya M. Nasrallah, and Lauren McCollum

Subjects
Continuum (measurement), Epidemiology, Health Policy, Disease, Biology, medicine.disease, Phenotype, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Atrophy, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, Neuroscience
Published
2020

16. Identification of blood eQTLs for AD risk loci

Author

Fabiana H.G. Farias, Carlos Cruchaga, John P. Budde, Joseph Bradley, Richard Davenport, Zeran Li, Alzheimer’s Disease Neuroimaging Initiative, Yuetiva Deming, Benjamin Saef, Oscar Harari, and Fengxian Wang

Subjects
Genetics, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Identification (biology), Neurology (clinical), Disease, Geriatrics and Gerontology, Biology
Published
2020

17. MRI decline pattern in early onset MCI due to Alzheimer’s disease

Author

Raquel Sánchez-Valle, José Contador, Alzheimer’s Disease Neuroimaging Initiative, Albert Lladó, Roser Sala-Llonch, Sergi Borrego-Écija, Mircea Balasa, and Agnés Pérez‐Millan

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease progression, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Internal medicine, medicine, Cardiology, Neurology (clinical), Geriatrics and Gerontology, business, Early onset
Published
2020

18. β‐amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline

Author

Paul K. Crane, Xin Xing, Gongbo Liang, Fanny M. Elahi, Nathan Jacobs, David W.L. Ma, Alzheimer’s Disease Neuroimaging Initiative, Ai-Ling Lin, Qiang Cheng, Tyler C. Hammond, Kwangsik Nho, and David A. Ziegler

Subjects
Epidemiology, business.industry, Health Policy, Disease progression, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, β amyloid, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience
Published
2020

19. Integration of demographics, genetics, imaging and metabolomics data to identify Alzheimer’s disease patients

Author

Vincent Chouraki, Alzheimer’s Disease Neuroimaging Initiative, Philippe Amouyel, Céline Bellenguez, Vincent Damotte, Guillemette Marot, and Aline Meirhaeghe

Subjects
0303 health sciences, Demographics, Epidemiology, business.industry, Health Policy, 010401 analytical chemistry, Disease, Bioinformatics, 01 natural sciences, 0104 chemical sciences, Metabolomics data, 03 medical and health sciences, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, 030304 developmental biology
Published
2020

20. Synaptic proteins relate to memory scores in preclinical Alzheimer’s disease and cognitively healthy controls depending on amyloid

Author

Johan Gobom, Charlotte E. Teunissen, Frans R.J. Verhey, Kaj Blennow, Mikel Tainta, Rik Vandenberghe, Alzheimer’s Disease Neuroimaging Initiative, Gwendoline Peyratout, Betty M. Tijms, Julius Popp, Simon Lovestone, Johannes Streffer, Magda Tsolaki, Henrik Zetterberg, Stephanie J.B. Vos, Isabelle Bos, Kirsten E. J. Wesenhagen, Yvonne Freund-Levi, Philip Scheltens, Pablo Martinez-Lage, and Pieter Jelle Visser

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Amyloid, Epidemiology, business.industry, Health Policy, Medicine, Neurology (clinical), Disease, Geriatrics and Gerontology, business, Neuroscience
Published
2020

21. Stage‐dependent amyloid beta‐ and tau‐associated longitudinal white matter degeneration in early stages of Alzheimer’s disease

Author

Joseph Lim, Kwun Kei Ng, Ashwati Vipin, Juan Helen Zhou, Fang Ji, Ofer Pasternak, Hee Youn Shim, and Alzheimer’s Disease Neuroimaging Initiative

Subjects
Pathology, medicine.medical_specialty, biology, Epidemiology, Amyloid beta, business.industry, Health Policy, Early detection, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, White matter degeneration, medicine, biology.protein, Neurology (clinical), Geriatrics and Gerontology, Stage (cooking), business
Published
2020

22. Stages of tau aggregation associated with amyloidosis reflected in non‐negative matrix factorization components

Author

Jimit Doshi, Christos Davatzikos, Alzheimer’s Disease Neuroimaging Initiative, Aristeidis Sotiras, Ilya M. Nasrallah, David A. Wolk, Guray Erus, Dhivya Srinivasan, and Monica Truelove-Hill

Subjects
Epidemiology, business.industry, Health Policy, Amyloidosis, Disease progression, medicine.disease, Non-negative matrix factorization, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, medicine, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience
Published
2020

23. Longitudinal change in CSF biomarkers, especially NPTX2, in non‐demented elderly predicts cognitive decline and conversion to dementia

Author

Doug R. Galasko, Denis S. Smirnov, David P. Salmon, and Alzheimer’s Disease Neuroimaging Initiative

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Internal medicine, Csf biomarkers, Medicine, Dementia, Prognostic biomarker, Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, business
Published
2020

24. Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study

Author

Jacques Touchon, Lan Tan, Hui-Fu Wang, John Suckling, Jie-Qiong Li, Chen-Chen Tan, Can Zhang, Xue-Ning Shen, Yan-Jiang Wang, Alzheimer’s Disease Neuroimaging Initiative, Lei Feng, Jin-Tai Yu, Qiang Dong, and Serge Gauthier

Subjects
Oncology, medicine.medical_specialty, Longitudinal study, Epidemiology, business.industry, Health Policy, Disease progression, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Internal medicine, medicine, Biomarker (medicine), Neurology (clinical), Geriatrics and Gerontology, business
Published
2020

25. Genetic risk prediction of late‐onset Alzheimer’s disease based on tissue‐specific transcriptomic analysis and polygenic risk scores

Author

Hong-Hee Won, Sang-Hyuk Jung, Dokyoon Kim, Alzheimer’s Disease Neuroimaging Initiative, and Kwangsik Nho

Subjects
Genetics, Epidemiology, Health Policy, Late onset, Disease, Biology, Transcriptome, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Tissue specific, Polygenic risk score, Neurology (clinical), Geriatrics and Gerontology, Genetic risk
Published
2020

26. Genetic associations with brain amyloidosis

Author

Murat Bilgel, Marilyn S. Albert, Matthew Schrag, Emily R. Mahoney, Timothy J. Hohman, David A. Bennett, Sterling C. Johnson, Theresa M. Harrison, Alzheimer’s Disease Neuroimaging Initiative, Philip L. De Jager, Corinne D. Engelman, Paul S. Aisen, Christopher D. Whelan, Jimmy Z. Liu, Yizhe Gao, Badri N. Vardarajan, William J. Jagust, David Goldstein, Neha S. Raghavan, Logan Dumitrescu, Hyun-Sik Yang, Elizabeth C. Mormino, Julie A. Schneider, Andrew J. Saykin, Keith A. Johnson, Richard Mayeux, Susan M. Resnick, Annie J. Lee, and Reisa A. Sperling

Subjects
Genetics, Epidemiology, business.industry, Health Policy, Amyloidosis, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2020

27. Discordant results in CSF/PET Aβ biomarkers are dependent on APOE genotype and related to inter‐individual differences in CSF Aβ42, Aβ40 and Aβ38 isoforms

Author

Arianna Sala, Elena Rodriguez-Vieitez, Alzheimer’s Disease Neuroimaging Initiative, and Agneta Nordberg

Subjects
Apolipoprotein E, Gene isoform, Epidemiology, business.industry, Health Policy, Bioinformatics, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neuroimaging, Genotype, Biomarker (medicine), Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2020

28. P2-389: DETECTION OF AMYLOID-POSITIVE COGNITIVELY UNIMPAIRED INDIVIDUALS USING VOXEL-BASED MACHINE LEARNING ON STRUCTURAL LONGITUDINAL BRAIN MRI

Author

Verónica Vilaplana, Miquel Artigues, Raffaele Cacciaglia, Adrià Casamitjana, Alzheimer’s Disease Neuroimaging Initiative, Carles Falcon, José Luis Molinuevo, Grégory Operto, Paula M. Petrone, and Juan Domingo Gispert

Subjects
Amyloid, Epidemiology, business.industry, Health Policy, computer.software_genre, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Voxel, Brain mri, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience, computer
Published
2019

29. P3-219: EEG EVIDENCE OF COMPENSATORY MECHANISMS IN PRECLINICAL ALZHEIMER'S DISEASE

Author

Geoffroy Gagliardi, Delphine Oudiette, Federico Raimondo, Marie-Odile Habert, Sinead Gaubert, Marie-Constance Corsi, Jacobo D. Sitt, Hovagim Bakardjian, Fabrizio De Vico Fallani, Marion Houot, Bruno Dubois, Alzheimer’s Disease Neuroimaging Initiative, Bertrand Hermann, Lionel Naccache, and Stéphane Epelbaum

Subjects
medicine.diagnostic_test, Epidemiology, business.industry, Health Policy, Disease, Electroencephalography, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience
Published
2019

30. P4‐244: MITOCHONDRIAL HAPLOGROUPS AND A NUCLEAR ENCODED MITOCHONDRIAL POLYGENIC RISK SCORE INTERACT TO INFLUENCE DEMENTIA RISK

Author

Shea J. Andrews, Tim W McInerney, Alden L. Gross, Christopher Patterson, Alzheimer’s Disease Neuroimaging Initiative, Alison Goate, Judy Pa, Elias K. Michaelis, Russell H. Swerdlow, G. Peggy McFall, and Brian Fulton-Howard

Subjects
Genetics, Epidemiology, Health Policy, Biology, medicine.disease, Haplogroup, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Dementia, Polygenic risk score, Neurology (clinical), Geriatrics and Gerontology
Published
2018

31. P2‐230: CHALLENGES ASSOCIATED WITH BIOMARKER‐BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE

Author

Alzheimer’s Disease Neuroimaging Initiative, Rafael Blesa, Victor Montal, Juan Fortea, Eduard Vilaplana, Maria Carmona-Iragui, Jordi Pegueroles, Daniel Alcolea, Mony J. De Leon, Raquel Sánchez-Valle, Alberto Lleó, and Ignacio Illán-Gala

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Biomarker (medicine), Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

32. P2‐510: MACHINE LEARNING APPROACHES FOR IDENTIFYING AMYLOID POSITIVITY BASED ON NEUROPSYCHOLOGICAL TEST PERFORMANCE WITH DEMOGRAPHICS IN NONDEMENTED POPULATION

Author

Hong-Gee Kim, Alzheimer’s Disease Neuroimaging Initiative, and Hyunwoong Ko

Subjects
education.field_of_study, Amyloid, medicine.diagnostic_test, Demographics, Epidemiology, business.industry, Health Policy, Population, Neuropsychological test, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, education, business, Clinical psychology
Published
2018

33. P4‐308: MODELLING THE ASSOCIATIONS BETWEEN [18F]AV1451, [18F]FDG PET AND COGNITION IN MILD COGNITIVE IMPAIRMENT AND AD DEMENTIA

Author

Konstantinos Chiotis, Alzheimer’s Disease Neuroimaging Initiative, Elisa Colato, Elena Rodriguez-Vieitez, Agneta Nordberg, and Mariam S. Mazrina

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Cognition, Audiology, medicine.disease, 18f fdg pet, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment
Published
2018

34. P1‐049: COMPOSITE ENDPOINTS FOR ALZHEIMER'S DISEASE CLINICAL TRIALS: IMPROVED PERFORMANCE VIA OPTIMAL WEIGHTING OF COMPONENT MEASURES

Author

Alzheimer’s Disease Neuroimaging Initiative, Benjamin Shifflett, Nandini Raghavan, Steven D. Edland, Doug R. Galasko, Emily C. Edmonds, David P. Salmon, and Diane M. Jacobs

Subjects
0301 basic medicine, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Weighting, Clinical trial, 03 medical and health sciences, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Improved performance, 030104 developmental biology, 0302 clinical medicine, Physical medicine and rehabilitation, Developmental Neuroscience, Component (UML), medicine, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery
Published
2018

35. P3‐448: THE EFFECT OF AGE AND SEX ON EVALUATION OF HIPPOCAMPAL ATROPHY IN NORMAL AND MILD ALZHEIMER'S DISEASE DEMENTIA: A J‐ADNI STUDY

Author

Japanese Alzheimer's Disease Neuroimaging Initiative, Kaori Iwata, Hiroshi Matsuda, Akinori Nakamura, Yasuyuki Kimura, Go Kizawa, Takeshi Iwatsubo, Takashi Kato, Hideyuki Hattori, Yusuke Okada, Hiroshi Toyama, and Kengo Ito

Subjects
Pediatrics, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Age and sex, medicine.disease, Hippocampal atrophy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

36. P3‐405: THE EFFECT OF FIELD STRENGTH TOWARD LONGITUDINAL TOTAL INTRACRANIAL VOLUME ESTIMATION AND HIPPOCAMPAL ATROPHY ON ADNI DATA

Author

Karteek Popuri, Faisal Beg, Alzheimer’s Disease Neuroimaging Initiative, and Da Ma

Subjects
Epidemiology, Chemistry, business.industry, Health Policy, 05 social sciences, Field strength, 050105 experimental psychology, Hippocampal atrophy, 03 medical and health sciences, Psychiatry and Mental health, Cellular and Molecular Neuroscience, 0302 clinical medicine, Developmental Neuroscience, Intracranial volume, 0501 psychology and cognitive sciences, Neurology (clinical), Geriatrics and Gerontology, Nuclear medicine, business, 030217 neurology & neurosurgery
Published
2018

37. IC‐P‐170: A SIGNATURE OF BRAIN ATROPHY HIGHLY PREDICTIVE OF PROGRESSION TO ALZHEIMER'S DEMENTIA AND COGNITIVE DECLINE

Author

Pierre Bellec, Christian Dansereau, Sebastian Urchs, Pierre Orban, Alzheimer’s Disease Neuroimaging Initiative, John C.S. Breitner, Yasser Iturria Medina, and Angela Tam

Subjects
Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Atrophy, Developmental Neuroscience, medicine, Alzheimer s dementia, Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, business, Neuroscience
Published
2018

38. P4‐302: DISEASE‐STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITION, ATROPHY, AND TAU BURDEN IN ALZHEIMER'S DISEASE

Author

Michael W. Weiner, Alzheimer’s Disease Neuroimaging Initiative, and Duygu Tosun

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Cognition, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Atrophy, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, Stage specific, business
Published
2018

39. P3‐303: EFFECT OF BIOMARKERS ON RATE OF PROGRESSION: COMPARISON OF US‐ADNI AND J‐ADNI DATA

Author

Kanae Takahashi, Japanese Alzheimer's Disease Neuroimaging Initiative, Ichiro Arano, Noriaki Adachi, and Masashi Kikuchi

Subjects
Oncology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.medical_specialty, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

40. P3‐436: MECHANISTIC PROFILES OF NEURODEGENERATION: A STUDY IN ALZHEIMER'S DISEASE, HEALTHY AGEING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

Author

Wiro J. Niessen, Neil P. Oxtoby, Alzheimer’s Disease Neuroimaging Initiative, Marco Lorenzi, Meike W. Vernooij, Daniel C. Alexander, Sara Garbarino, Arman Eshaghi, Eline Vinke, Olga Ciccarelli, M. Arfan Ikram, Frederik Barkhof, and Razvan V. Marinescu

Subjects
Epidemiology, business.industry, Health Policy, Neurodegeneration, Primary Progressive Multiple Sclerosis, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Immunology, Medicine, Neurology (clinical), Healthy ageing, Geriatrics and Gerontology, business
Published
2018

41. P2‐117: ASSOCIATION OF ALZHEIMER'S DISEASE WITH ANDROGEN RECEPTOR VARIANTS AND PLASMA TESTOSTERONE LEVELS IMPLICATES DECREASED TESTOSTERONE SIGNALING IN NEURODEGENERATION

Author

Jennifer S. Yokoyama, Jessie S. Carr, Charles J. Ryan, Ethan G. Geier, Luke W. Bonham, and Alzheimer’s Disease Neuroimaging Initiative

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Neurodegeneration, Testosterone (patch), Disease, medicine.disease, Decreased testosterone, Androgen receptor, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

42. IC‐P‐193: DEVELOPMENT AND VALIDATION OF A NOVEL DEMENTIA OF THE ALZHEIMER'S TYPE (DAT) SCORE BASED ON METABOLISM FDG‐PET IMAGING

Author

Rakesh Balachandar, Kathryn I. Alpert, Karteek Popuri, Ging-Yuek Robin Hsiung, Alzheimer’s Disease Neuroimaging Initiative, Ian R. A. Mackenzie, Lei Wang, Donghuan Lu, Mahadev Bhalla, and Faisal Beg

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

43. P2‐003: ACETYLCHOLINESTERASE INHIBITOR THERAPY IN MILD COGNITIVE IMPAIRMENT: YES OR NO?

Author

Liana G. Apostolova, Kwangsik Nho, Krisztina Marosi, Sophie Sokolow, Alzheimer’s Disease Neuroimaging Initiative, and Jerome I. Rotter

Subjects
Epidemiology, medicine.drug_class, business.industry, Health Policy, Pharmacology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Acetylcholinesterase inhibitor, medicine, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment
Published
2018

44. P2‐287: A δ HOMOLOG FOR DEMENTIA CASE FINDING WITH REPLICATION IN ADNI

Author

Ram J. Bishnoi, Alzheimer’s Disease Neuroimaging Initiative, Raymond F. Palmer, and Donald R. Royall

Subjects
Genetics, Epidemiology, Health Policy, Biology, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Replication (statistics), medicine, Case finding, Dementia, Neurology (clinical), Geriatrics and Gerontology
Published
2018

45. O2‐11‐06: BLOOD‐BASED PROTEIN PREDICTORS OF DEMENTIA SEVERITY AS MEASURED BY δ: REPLICATION ACROSS BIOFLUIDS AND COHORTS

Author

Ram J. Bishnoi, Alzheimer’s Disease Neuroimaging Initiative, Raymond F. Palmer, and Donald R. Royall

Subjects
Oncology, medicine.medical_specialty, Epidemiology, Health Policy, Biology, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, Replication (statistics), medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology
Published
2018

46. P1‐380: MRI CLASSIFIERS CHARACTERIZE MILD TRAUMATIC BRAIN INJURY IN SYMPTOMATIC AND PRESYMPTOMATIC STAGES AND DIFFERENTIATE FROM ALZHEIMER'S DISEASE–RELATED IMPAIRMENT

Author

Dawn C. Matthews, Alzheimer’s Disease Neuroimaging Initiative, Virendra Mishra, Charles Bernick, Jeffrey L. Cummings, Ana S. Lukic, Sarah J. Banks, and Randolph D. Andrews

Subjects
Pathology, medicine.medical_specialty, Epidemiology, Traumatic brain injury, business.industry, Health Policy, Disease, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

47. IC‐P‐224: HETEROGENEOUS TAU‐PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY

Author

Yasser Iturria Medina, Jacob W. Vogel, Suzanne L. Baker, Rik Ossenkoppele, Alan C. Evans, Alzheimer’s Disease Neuroimaging Initiative, Oskar Hansson, and Gregory Kiar

Subjects
Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Hippocampus, Signal, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

49. P2‐409: PERIPHERAL INFLAMMATION AND BRAIN GLUCOSE METABOLISM IN NONDEMENTED OLDER ADULTS

Author

Alzheimer’s Disease Neuroimaging Initiative, Meredith N. Braskie, and Paul M. Thompson

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Inflammation, Carbohydrate metabolism, Peripheral, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, medicine.symptom, business
Published
2018

50. O2‐15‐05: CSF IMMUNE MARKERS PREDICT DECREASED AD SYMPTOM SEVERITY AND PROGRESSION

Author

Pierre-François Meyer, Alzheimer’s Disease Neuroimaging Initiative, Judes Poirier, Melissa Savard, and John C.S. Breitner

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Immunology, Symptom severity, Medicine, Immune markers, Neurology (clinical), Geriatrics and Gerontology, business
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results